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Available online 31 January 2018Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) is the
most common form of hereditary stroke disorder. It is caused by mutations in NOTCH3 that lead to progressive
degeneration of the smooth muscle cells in blood vessels. There is currently no treatment for this disorder. We
reprogrammed to pluripotency blood mononuclear cells isolated from a patient carrying a NOTCH3 mutation
by using a commercially available non-integrating system. The success in the generation of this iPSC line
(IDISi001-A) suggests that the NOTCH3mutation did not limit cell reprogramming and offers an unprecedented
opportunity for studying and modeling CADASIL pathology.
© 2018 Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://
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believe that the generation of human iPSC-derived muscle cells from
CADASIL patients will facilitate gene-editing approaches for develop-
mental biology studies as well as for disease modeling and drug
screening.Resource details
CADASIL is deﬁned as cerebral autosomal dominant arteriopathy
produced by the mutation of the NOTCH3 gene (Joutel et al., 2000).
The main neurological symptoms of CADASIL include migraine with
aura, psychiatric problems, ischemic episodes, and cognitive deﬁcits.
This disease causes degeneration of the smoothmuscle due to the depo-
sition of granular osmiophilicmaterial within the basal lamina, progres-
sive loss of smoothmuscle cells, and ﬁbrosis of themedia layer ofmicro-
arteries (Chabriat et al., 2009). Currently, the experimental modeling of
CADASIL is restricted to the use of Notch3 knockout mice, which, how-
ever, present important limitations in reproducing the phenotype of
this disease (Ayata, 2010).
In this study, we report for ﬁrst time the generation of a human iPSC
line from a patientwith CADASIL carrying aNOTCH3 Arg N Cysmutation
at codon 1242 of exon 23. Human peripheral blood mononuclear cells
(PBMCs) from this patient were reprogrammed into iPSCs (IDISi001-
A) using the non-integrative CytoTune iPS 2.0 Reprograming System
(Thermo Fisher Scientiﬁc) to deliver Yamanaka's factors OCT4, SOX2,
KLF4, and c-Myc. iPSCs colony formation was observed daily. Colo-
nies had characteristic round-shaped morphology with refracting
borders and contained small round-shaped cells with a large nu-
cleus/cytoplasm ratio. After 3 months, the ﬁrst colonies were frozen.
During the reprogramming process, the alkaline phosphatase test
was used to select the potential pluripotent colonies (Fig. 1A). Once
the cell line was established, the following standard tests were car-
ried out: A) PCR analysis for the absence of mycoplasma (Supple-
mental Fig. 1); B) PCR analysis to conﬁrm the loss of the Sendai
virus (SeV) used for the reprogramming (Supplemental Figs. 2 and
3); C) short tandem repeat (STR) analysis used to demonstrate that
the generated iPSCs genetically matched donor's cells (Supplemen-
tal Fig. 4); and D) PCR analysis of the NOTCH3 gene to conﬁrm the
presence of the mutation in the iPSCs (Supplemental Fig. 5). Subse-
quently, the expression of the membrane and nuclear pluripotency
markers (Tra-1-60, SSEA4, SOX-2, OCT-4, and NANOG, using the an-
tibodies showed in Table 1) was evaluated by immunoﬂuorescence
analysis (Fig. 1B). Cells from the new iPSC line were spontaneously
differentiated in vitro into the three germ layers by the induction
of embryoid body (EB) formation (Fig. 1C). Expression levels of
genes encoding transcription factors essential to maintain pluripo-
tent embryonic stem cell phenotype (SOX2, OCT4, and NANOG)
were evaluated by qPCR in different clones (#42.2, #53.3, #76.2,
#78B.2, #83.3, #80.3) derived from the same cell line. These results
were compared to those obtained with a human foreskin ﬁbroblast
(HFF) cell line, used as SeV-uninfected cell control, and to those in al-
ready characterized iPSC positive control cells (iPSCs C+) (Fig. 1D).
In addition, the presence of the mutation previously diagnosed in
the patient in IDISi001-A cells was conﬁrmed by forward and reverse
sequencing of the corresponding NOTCH3 fragment (Fig. 1E, panels 1
and 2, respectively) and compared to the results of similar sequenc-
ing of the same fragment from a healthy subject without NOTCH3
mutation (Fig. 1E; panels 3 and 4, respectively). Finally, the karyo-
type of the new reprogrammed cell line showed a normal chromo-
somal proﬁle, with no abnormalities (Fig. 1F). In conclusion, we
believe that the generation of a human iPSC line from a CADASIL pa-
tient will facilitate studies of developmental biology and stimulate
disease modeling for drug screening and therapeutic gene-editing
approaches for this important cerebral arteriopathy (see Graphical
abstract) (Table 2).Materials and methods
Reprogramming of CADASIL-PBMCs
A peripheral blood sample was taken from a patient diagnosed with
CADASIL, whose mutation was located at codon 1243 of exon 23 of
NOTCH3 (genotype: Arg1242Cys/normal). This mutation had not been
reported before. The mutation was analyzed by sequencing the entire
coding region of the gene (new generation sequencing technique,
SOLID 5500XL, Thermo Fisher Scientiﬁc).
To obtain PBMCs, the blood sample was mixed with PBS + 2% FBS
and centrifuged in a SepMate-50 tube (StemCell Technologies) with
Lymphoprep (StemCell Technologies) in a density gradient.
Before reprogramming, PBMCs were cultured for 3 days using
Stempro-34 SFM (Gibco) with cytokines (StemCell Technologies).
Reprogramming was performed using a CytoTune-iPS 2.0 Sendai
Reprogramming Kit (Thermo Fisher Scientiﬁc). Three hundred thou-
sand cells were infected at the following multiplicity of infection
(MOI) values: KOS = 5; c-MYC = 5; KLF4 = 3.
Cell culture
Cells were cultured inmTeSR1medium (StemCell Technologies). On
the ﬁrst and second passage, cells were maintained in the wells of a 12-
well plate. On the third passage, they were transferred into wells of a 6-
well plate, and from passage four and thereafter, they were cultured in
35-mm Petri dishes. All wells and dishes were coated with Matrigel™
matrix (Corning). For the ﬁrst and second passages, colonies were se-
lected and pickedwith the help of anOrigio Stripper (Origio)with Strip-
per tips (Origio) of 175 μm in diameter. Later passages were performed
mechanically, using cell lifters.
PCR and qPCR
Total RNA from undifferentiated IDISi001-A cell line, human ﬁbro-
blasts (considered as negative control), and a previously established
iPSC line was isolated using a Quick-RNA™ MiniPrep kit (Zymo Re-
search) and quantiﬁed with Nanodrop (Thermo Fisher Scientiﬁc). For
RT-PCR, 1 μg of cDNA was generated using a iScriptTM cDNA Synthesis
Kit (BIORAD) following the manufacturer's instructions. PCR to analyze
the presence/absence of SeV was performed using a Ready Mix REDTaq
PCR ReactionMix (Sigma-Aldrich). For qPCR, iTaq Universal SYBRGreen
Supermix (BIORAD) was used. In order to check for the expression of
pluripotency factors, qPCR for NANOG, OCT4, and SOX2was performed.
Table 1 shows all primer sequences used for PCR and qPCR. All
primers (they came lyophilized butwere diluted to aﬁnal concentration
of 100 μMwith nuclease-free H2O)were designed in-house and ordered
from Sigma-Aldrich.
Alkaline phosphatase
For the alkaline phosphatase (AP) test, an AP Live Stain Kit (Thermo
Fisher Scientiﬁc) was used. This test was performed always after
3–5 days of cell culture based on plate conﬂuence and according to
the manufacturer's instructions. Colonies were not affected by the pro-
cess and kept growing normally after the AP test.
Immunocytochemistry
Immunocytochemistry tests for the pluripotency nuclear markers
SSEA4 and TRA1–60 and for the pluripotency membrane markers
SOX2 and OCT4 were performed using a Pluripotent Stem Cell 4-
Marker Immuno Kit (Thermo Fisher Scientiﬁc) according to the manu-
facturer's instructions.
To analyze NANOG (Thermo Fisher Scientiﬁc) expression, a
standard immunocytochemistry protocol from our lab was
Fig. 1. Representation of IDISi001-A iPSC line characterization.
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phenylindole (DAPI).Karyotyping
Cells were blocked in their metaphase by incubating them with
Colcemid (Gibco) for 3 h. Then, the cells were detached by adding
Table 1
Characterization and validation.
Classiﬁcation Test Result Data
Morphology Photography Normal Not shown but available from the authors upon
request
Phenotype Immunocytochemistry OCT4, NANOG, SOX2, SSEA4, TRA-1-60 Fig. 1, panel B
RT-qPCR Relative gene expression: SOX2, OCT4,
NANOG
Fig. 1, panel D
Genotype Karyotype (G-Banding) 46XY, Resolution 400 Fig. 1, panel F
Identity Microsatellite PCR (mPCR) OR Short tandem repeat analysis Fig. 4, supplementary ﬁle
short tandem repeat analysis Not performed N/A
Mutation analysis (IF
APPLICABLE)
Sequencing Heterozygous Diagnostic available from the authors upon
request
Southern blot OR whole genome
sequencing
Substitution Fig. 1, panel E
Microbiology and virology Mycoplasma Negative Fig. 1, supplementary
Differentiation potential Embryoid body formation FOXA-2, vimentin, nestin Fig. 1, panel C
Donor screening (OPTIONAL) HIV 1 + 2 Hepatitis B, Hepatitis C Not performed Not available
Genotype additional info
(OPTIONAL)
Blood group genotyping Not performed Not available
HLA tissue typing Not performed Not available
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PBS. After that, they were centrifuged and exposed to a hypotonic
0.075 M KCL solution for 10 min at 37 °C. Cells were then ﬁxed by the
triple exposure to methanol/glacial acetic acid mixture (3:1). To check
the karyotypes, Giemsa staining was performed. A total of 29 meta-
phases were analyzed, all of which were normal without any kind of
chromosomal anomalies.
Analysis of the mutation
The NOTCH3 fragment containing the mutation was ampliﬁed by
PCR. The samples were sequenced by New Generation Sequencing
using a SOLID 5500XL genetic analyzer.
In vitro embryoid body formation and differentiation
Once a Petri dish reached approximately 85% conﬂuence, colonies
were washed carefully with DMEM-F12 and after that, Embryoid Body
Medium with 20% FBS (EBM20%) was added. This medium contained
DMEM-F12 with Glutamax, 20% FBS, non-essential aminoacids 1×
(Gibco), P/S 1×, and 50 mM β-mercaptoethanol (Gibco).Table 2
Reagents details.
Antibodies used for immunocytochemistry/ﬂow-cytometry
Antibody





Differentiation markers Rabbit anti-FOXA2
Rabbit anti-vimentin
Rabbit anti-nestin
Secondary antibodies Alexa Fluor 488 Goat anti-mouse IgG3
Alexa Fluor 594 Donkey anti-rabbit
Alexa Fluor 488 Donkey anti-rat
Alexa Fluor 594 Goat anti-mouse IgM




Episomal plasmids (qPCR) SeV plasmid
Pluripotency markers (qPCR) NANOG
OCT4
SOX2
Housekeeping genes (qPCR) GAPDHColonies were cutmaking a grid pattern with the aid of a sterile 200-μL
pipette and then, theywere detached from the plate eithermechanically or
enzymatically (Dispase solution, StemCell Technologies). Once detached,
clusters were transferred to a well of an ultra-low 6-well attachment
plate (Corning) with EBM20% plus 10 μM ROCK inhibitor (StemCell
Techonologies). EBs already formed at day 1. EBs were maintained for
7 days with medium replacement every other day. On day 7, EBs were
transferred into a chamber slide (Sarstedt) previously coated with
Matrigel™, 6–7 EBs per well, to allow their attachment and differentiation.
EBs inside the chamber slides were maintained for 14 days in EBM20%
(plus ROCK inhibitor just theﬁrst plating day), before performing immuno-
cytochemistry experiments.
For the characterization of the three germ layers, the endodermwas
identiﬁed using an anti-FOXA2 antibody (Thermoﬁsher; 1:100 dilu-
tion), the mesoderm was identiﬁed using an anti-vimentin antibody
(Bioss Antibodies; 1:100 dilution), whereas the ectodermwas identiﬁed
using an anti-nestin antibody (Abcam; 1:200 dilution).
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